Showing results (91-100 of 148) with videos related to

Sort By:
Pageof 15
Anesthesia and Analgesia|December 1, 1990
Nitrous oxide and epinephrine-induced arrhythmiasG H Lampe, J H Donegan, S M Rupp, et al.
Mbio|July 4, 2019
Population Structure, Molecular Epidemiology, and β-Lactamase Diversity among Stenotrophomonas maltophilia Isolates in the United StatesMaria F Mojica, Joseph D Rutter, Magdalena Taracila, et al.
Genome Biology|July 22, 2015
A novel method of consensus pan-chromosome assembly and large-scale comparative analysis reveal the highly flexible pan-genome of Acinetobacter baumanniiAgnes P Chan, Granger Sutton, Jessica DePew, et al.
Viruses|April 23, 2022
Identification and Characterization of vB_PreP_EPr2, a Lytic Bacteriophage of Pan-Drug Resistant Providencia rettgeriJaime L Mencke, Yunxiu He, Andrey A Filippov, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 2, 2000
Pseudomonas syringae Hrp type III secretion system and effector proteinsA Collmer, J L Badel, A O Charkowski, et al.
Pediatric Obesity|December 10, 2025
Central Adiposity, Rather Than in Utero Exposure to Maternal Obesity or Gestational Diabetes, Predicts Metabolic Syndrome Risk in Children Aged 4-10 YearsDaniel O Mensah, Alysha B Everett, Amelia E Fouts, et al.
Diagnostic Microbiology and Infectious Disease|July 10, 2018
Sequence heterogeneity of the PenA carbapenemase in clinical isolates of Burkholderia multivoransScott A Becka, Elise T Zeiser, Steven H Marshall, et al.
Virology Journal|May 30, 2013
Whole genome sequencing and comparative genomic analyses of two Vibrio cholerae O139 Bengal-specific Podoviruses to other N4-like phages reveal extensive genetic diversityDerrick E Fouts, Jochen Klumpp, Kimberly A Bishop-Lilly, et al.
Pediatric Obesity|October 20, 2023
Leptin resistance in children with in utero exposure to maternal obesity and gestational diabetesAlysha B Everett, W Timothy Garvey, Jose R Fernandez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2008
A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumorsElizabeth Fox, John M Maris, Brigitte C Widemann, et al.
Pageof 15